Caricamento...
AT-39 A RANDOMIZED PHASE II TRIAL OF VANDETANIB (ZD6474) IN COMBINATION WITH CARBOPLATIN VERSUS CARBOPLATIN ALONE IN ADULTS WITH RECURRENT GLIOBLASTOMA
BACKGROUND: Vandetanib is a tyrosine kinase inhibitor of VEGFR-2, EGFR, and the RET oncogene. While vandetanib has not shown significant clinical activity, preclinical experience suggests synergistic efficacy in combination with carboplatin in glioblastoma (GBM). METHODS: This randomized non-compara...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4217817/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.38 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|